Investors Flock to Arrowhead Pharmaceuticals as Shares Skyrocket Nearly Fivefold, Sparking Hopes of Continued Momentum

Table of Contents Arrowhead Pharmaceuticals (ARWR) has delivered extraordinary returns over the last twelve months, skyrocketing 481%. The momentum continued Tuesday as shares climbed 3.9% to settle at $71.92, driven by a Morgan Stanley upgrade and an ambitious new price objective of $100. Arrowhead Pharmaceuticals, Inc., ARWR The $100 price target suggests potential upside of approximately 39% from Tuesday’s close. Morgan Stanley’s Michael Ulz elevated his rating to Overweight from Equal-weight, pointing to forthcoming Phase 3 trial data that he believes will “reveal a multibillion-dollar market opportunity currently underestimated by investors.” The focal point is plozasiran, Arrowhead’s flagship investigational therapy targeting patients diagnosed with severe hypertriglyceridemia (SHTG) — a metabolic disorder characterized by dangerously elevated triglyceride levels that heighten cardiovascular and pancreatitis risks. Phase 3 trial results are scheduled for release during the third quarter of 2026. Drawing on earlier-stage data and comparable patient studies, Ulz anticipates favorable outcomes. A successful readout could represent a pivotal milestone for Arrowhead’s evolution. Morgan Stanley was not the sole institution revising estimates upward. BofA similarly lifted its price objective, projecting peak annual revenues near $3 billion for plozasiran in the SHTG indication — signaling increasing analyst confidence in the drug’s commercial trajectory. Ulz revised his peak sales projection from $1.7 billion to $3.2 billion — an increase of nearly 90%. This substantial adjustment underscores growing optimism about the therapy’s addressable market, particularly among high-risk patients prone to acute pancreatitis. Arrowhead is not operating without rivals in this therapeutic area. Ionis Pharmaceuticals (IONS) is advancing olezarsen, another candidate targeting SHTG. Ulz noted that Ionis “has established pricing benchmarks” within this market segment. Olezarsen currently holds approval exclusively for familial chylomicronemia syndrome but has earned Breakthrough Therapy designation from regulators. A supplemental filing is under accelerated regulatory assessment, with a decision deadline set for June 30. Despite competitive dynamics, Ulz maintains that the market can support multiple therapies. He views plozasiran as possessing distinct standalone value, particularly for patients experiencing recurrent pancreatitis episodes. Arrowhead filed its inaugural New Drug Application for plozasiran in the fourth quarter of 2024. This submission represents a strategic inflection point — transforming the organization from a research-oriented biotech into a potential commercial-stage pharmaceutical company. The firm has established expertise in RNA interference technology. It acquired Roche’s RNAi operations in 2011, followed by Novartis RNAi assets in 2015. Johnson & Johnson’s Janssen division maintained a collaboration until 2023, when Janssen restructured its infectious disease and vaccine initiatives. Among the 12 analyst firms monitored by FactSet that cover ARWR, ten assign Buy ratings or equivalents. Only two firms — Leerink Partners and Bernstein Research — maintain Hold ratings. ARWR has advanced 8.2% year-to-date in 2026. By contrast, Ionis has declined 6.2% in the same period, though it has appreciated 156% over the past twelve months. Arrowhead’s market capitalization currently stands at $9.94 billion.